BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34976053)

  • 1. Optimal Strategy for Colorectal Cancer Patients' Diagnosis Based on Circulating Tumor Cells and Circulating Tumor Endothelial Cells by Subtraction Enrichment and Immunostaining-Fluorescence In Situ Hybridization Combining with CEA and CA19-9.
    Luo S; Ou Y; Zheng T; Jiang H; Wu Y; Zhao J; Zhang Z
    J Oncol; 2021; 2021():1517488. PubMed ID: 34976053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined detection and subclass characteristics analysis of CTCs and CTECs by SE-iFISH in ovarian cancer.
    Cheng H; Wang S; Luan W; Ye X; Dou S; Tang Z; Zhu H; Lin PP; Li Y; Cui H; Chang X
    Chin J Cancer Res; 2021 Apr; 33(2):256-270. PubMed ID: 34158744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Tumor-Derived Endothelial Cells: An Effective Biomarker for Breast Cancer Screening and Prognosis Prediction.
    Han T; Zhang J; Xiao D; Yang B; Chen L; Zhai C; Ding F; Xu Y; Zhao X; Zhao J
    J Oncol; 2022; 2022():5247423. PubMed ID: 36072971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aneuploid subtypes of circulating tumor cells and circulating tumor-derived endothelial cells predict the overall survival of advanced lung cancer.
    Zhang J; Hong Y; Wang L; Hu W; Tian G; Wu D; Wang Y; Dai L; Zhang Z; Yang Y; Fang J
    Front Oncol; 2023; 13():829054. PubMed ID: 37213309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly Correlated Recurrence Prognosis in Patients with Metastatic Colorectal Cancer by Synergistic Consideration of Circulating Tumor Cells/Microemboli and Tumor Markers CEA/CA19-9.
    Chu HY; Yang CY; Yeh PH; Hsu CJ; Chang LW; Chan WJ; Lin CP; Lyu YY; Wu WC; Lee CW; Wu JK; Jiang JK; Tseng FG
    Cells; 2021 May; 10(5):. PubMed ID: 34068719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant diagnostic value of circulating tumour cells in colorectal cancer.
    Yu H; Ma L; Zhu Y; Li W; Ding L; Gao H
    Oncol Lett; 2020 Jul; 20(1):317-325. PubMed ID: 32565958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic diagnostic value of circulating tumor cells and tumor markers CEA/CA19-9 in colorectal cancer.
    Cai M; He H; Hong S; Weng J
    Scand J Gastroenterol; 2023 Jan; 58(1):54-60. PubMed ID: 35968572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas.
    Li M; Gao F; Ren X; Dong G; Chen H; Lin AY; Wang DD; Liu M; Lin PP; Shen S; Jiang H; Yang C; Zhang X; Zhao X; Zhu Q; Li M; Cui Y; Lin S
    Cancer Sci; 2022 Oct; 113(10):3535-3546. PubMed ID: 35940591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of phenotyping and karyotyping of detecting circulating tumor cells in renal cell carcinoma using subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH).
    Tian D; Zhang M; Zheng G; Zhang Y; Li Y; Lin P; Li H; Jiao W; Niu H
    Int Urol Nephrol; 2020 Dec; 52(12):2281-2287. PubMed ID: 32748196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alu-based cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer.
    Qi J; Qian C; Shi W; Wu X; Jing R; Zhang L; Wang Z; Ju S
    Clin Biochem; 2013 Jan; 46(1-2):64-9. PubMed ID: 22975639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis.
    Zhu HH; Liu YT; Feng Y; Zhang LN; Zhang TM; Dong GL; Xing PY; Wang HY; Shi YK; Hu XS
    Thorac Cancer; 2021 Oct; 12(20):2749-2757. PubMed ID: 34423906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study on ctDNA and tumor DNA mutations in lung cancer and benign cases with a high number of CTCs and CTECs.
    Xie J; Hu B; Gong Y; He S; Lin J; Huang Q; Cheng J
    J Transl Med; 2023 Dec; 21(1):873. PubMed ID: 38041139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA19-9 as a marker of circulating tumor cells in first reflux blood of colorectal cancer patients.
    Zhao JX; Liu LR; Yang XY; Liu F; Zhang ZG
    Oncotarget; 2017 Sep; 8(40):67918-67932. PubMed ID: 28978084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Value of Combined Detection of Serum sTim-3 and CEA or CA19-9 for Postoperative Recurrence of Colorectal Cancer Diagnosis.
    Hong J; Chen X; Chen L; Wang Y; Huang B; Fang H
    Cancer Manag Res; 2023; 15():563-572. PubMed ID: 37426393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of detecting circulating tumor cells in colorectal cancer using subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH).
    Wu W; Zhang Z; Gao XH; Shen Z; Jing Y; Lu H; Li H; Yang X; Cui X; Li Y; Lou Z; Liu P; Zhang C; Zhang W
    Oncotarget; 2017 Mar; 8(13):21639-21649. PubMed ID: 28423493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic value of serum carcino-embryonic antigen, alpha fetoprotein and carbohydrate antigen 19-9 for colorectal cancer.
    Wang YR; Yan JX; Wang LN
    J Cancer Res Ther; 2014 Dec; 10 Suppl():307-9. PubMed ID: 25693941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cell enumeration for improved screening and disease detection of patients with colorectal cancer.
    Tsai WS; Hung WS; Wang TM; Liu H; Yang CY; Wu SM; Hsu HL; Hsiao YC; Tsai HJ; Tseng CP
    Biomed J; 2021 Dec; 44(6 Suppl 2):S190-S200. PubMed ID: 35292267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can preoperative CEA and CA19-9 serum concentrations suggest metastatic disease in colorectal cancer patients?
    Stojkovic Lalosevic M; Stankovic S; Stojkovic M; Markovic V; Dimitrijevic I; Lalosevic J; Petrovic J; Brankovic M; Pavlovic Markovic A; Krivokapic Z
    Hell J Nucl Med; 2017; 20(1):41-45. PubMed ID: 28315907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The stool
    Zhan Y; Wang S; Yuan Z; Zhao X; Ni K; Xin R; Zhou X; Liu Z; Yin X; Ping H; Liu Y; Wang W; Yan S; Han Q; Zhang X; Zhang Q; Liu Y; Zhang C
    Transl Cancer Res; 2023 Jan; 12(1):65-77. PubMed ID: 36760372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic models based on postoperative circulating tumor cells can predict poor tumor recurrence-free survival in patients with stage II-III colorectal cancer.
    Wang D; Yang Y; Jin L; Wang J; Zhao X; Wu G; Zhang J; Kou T; Yao H; Zhang Z
    J Cancer; 2019; 10(19):4552-4563. PubMed ID: 31528219
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.